Role of biomarkers in developing new therapies for vascular disease (Q36771454)

16 August 2017

1 reference

title

Role of biomarkers in developing new therapies for vascular disease (English)

1 reference

16 August 2017

0 references

Christie M. Ballantyne

series ordinal

2

object named as

Christie M Ballantyne

1 reference

16 August 2017

Vijay Nambi

1

1 reference

16 August 2017

publication date

1 April 2007

1 reference

16 August 2017

published in

World Journal of Surgery

1 reference

16 August 2017

volume

31

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

676-681

1 reference

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00268-006-0712-2

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-006-0712-2

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-006-0712-2

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-006-0712-2

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-006-0712-2

Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-006-0712-2

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

1 reference

12 December 2020

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

1 reference

12 December 2020

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

12 December 2020

Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease

1 reference

12 December 2020

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Vascular biomarkers and surrogates in cardiovascular disease.

1 reference

12 December 2020

Human platelets release a paf-acether: acetylhydrolase similar to that in plasma

1 reference

12 December 2020

Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

1 reference

12 December 2020

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial

1 reference

12 December 2020

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke

1 reference

12 December 2020

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Direct proinflammatory effect of C-reactive protein on human endothelial cells

1 reference

12 December 2020

C-reactive protein levels and outcomes after statin therapy

1 reference

12 December 2020

C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study

1 reference

12 December 2020

Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

12 December 2020

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

12 December 2020

Concept and usefulness of cardiovascular risk profiles

1 reference

12 December 2020

10.1007/S00268-006-0712-2

Identifiers

DOI

1 reference

16 August 2017

1 reference